892039-23-5

892039-23-5 structure
892039-23-5 structure
  • Name: TAN-452
  • Chemical Name: TAN-452
  • CAS Number: 892039-23-5
  • Molecular Formula: C29H30N2O5
  • Molecular Weight: 486.56
  • Catalog: Signaling Pathways GPCR/G Protein Opioid Receptor
  • Create Date: 2020-11-28 18:41:52
  • Modify Date: 2024-01-11 09:07:59
  • TAN-452 is an orally active, selective peripherally acting δ-opioid receptor (DOR) antagonist with a Ki of 0.47 nM and a Kb of 0.21 nM. TAN-452 is an antagonist for μ-opioid receptor (MOR; Ki=36.56 nM and Kb=9.43 nM) and κ-opioid receptor (KOR; Ki=5.31 nM and Kb=7.18 nM). TAN-452, a derivative of Naltrindole, demonstrates low brain penetrability and attenuates morphine-induced side effects without affecting pain control[1].

Name TAN-452
Description TAN-452 is an orally active, selective peripherally acting δ-opioid receptor (DOR) antagonist with a Ki of 0.47 nM and a Kb of 0.21 nM. TAN-452 is an antagonist for μ-opioid receptor (MOR; Ki=36.56 nM and Kb=9.43 nM) and κ-opioid receptor (KOR; Ki=5.31 nM and Kb=7.18 nM). TAN-452, a derivative of Naltrindole, demonstrates low brain penetrability and attenuates morphine-induced side effects without affecting pain control[1].
Related Catalog
Target

Ki: 0.47 nM (DOR), 36.56 nM (MOR) and 5.31 nM (KOR)[1] Kb: 0.21 nM (DOR), 9.43 nM (MOR) and 7.18 nM (KOR)[1]

In Vivo TAN-452 (1, 3, 10 mg/kg for p.o. or 0.3, 1, 3 mg/kg for s.c.) suppresses morphine-induced emesis in ferrets[1]. TAN-452 (30 mg/kg/2 mL for PO or 3 mg/kg/mL for IV) has a T1/2 of 2.1 hours[1]. TAN-452 suppresses morphine-induced small intestinal transit (SIT) inhibition in a dose-dependent manner. Administration of TAN-452 at 30 mg/kg alone does not affect SIT[1]. TAN-452 (10, 30 mg/kg; s.c.) significantly suppresses morphine-induced antinociception 30 min after administration. TAN-452 (po) produces no effect up to 300 mg/kg[1]. Animal Model: Male ferrets (1.3-1.9 kg)[1] Dosage: 1, 3, 10 mg/kg (p.o.) or 0.3, 1, 3 mg/kg (s.c.) Administration: PO or SC; before morphine Result: Prevented morphine-induced emesis in half of the animals with orally administered of 1 mg/kg and completely abolished emesis at 3 and 10 mg/kg. Completely abolished emesis by subcutaneous injection at 0.3, 1, and 3 mg/kg. Animal Model: Crj:CD(SD) IGS male rats (7 weeks old)[1] Dosage: 30 mg/kg/2 mL for PO or 3 mg/kg/mL for IV (Pharmacokinetic Analysis) Administration: Orally or intravenously Result: Had a T1/2 of 2.1 hours, a CL of 78.1 mL/min•kg, a Vss of 12.1 L/kg, and a Cmax of 526 ng/mL.
References

[1]. Tsutomu Suzuki, et al. Pharmacological profile of TAN-452, a novel peripherally acting opioid receptor antagonist for the treatment of opioid-induced bowel syndromes. Life Sci. 2018 Dec 15;215:246-252.

Molecular Formula C29H30N2O5
Molecular Weight 486.56
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.